Testing PE0116 and PE0105 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests two experimental drugs, PE0116 and PE0105, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the combination is safe and effective for cancers like kidney, head and neck, cervical, or ovarian cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your cancer must be advanced and have not responded to or cannot tolerate standard treatments.
- You need to be in good enough health to carry out daily activities (ECOG score 0 or 1).
- You must have had no cancer treatment (chemotherapy, radiation, etc.) in the past 4 weeks.
- You cannot have active infections like hepatitis B or C, or HIV.
- You must agree to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and whether it can shrink tumors or slow their growth.
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
This study tests a combination of two experimental cancer-fighting drugs (CVL006 and 9MW2821) in patients with advanced solid tumors, particularly head and neck cancer. The goal is to see if this combination can slow tumor growth and improve outcomes in patients whose cancers have not responded to standard treatments.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.